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treatment pathways in a hypothetical NSCLC population in the UK with a baseline 
EGFR mutation prevalence of 16.6%. Model inputs included parameters describing 
mutation testing accuracy, treatment response (EGFR inhibitor, standard chemo 
therapy or best supportive care) and adverse events arising from treatment. Inputs 
were based on published literature and costs in the NHS in England and Wales. The 
model examined cost-effectiveness over the patients’ lifetime. A one-way sensitivity 
analysis was conducted. Results: Using £32,500/QALY as a threshold, the cobas EGFR 
Mutation Test was cost-effective at an incremental cost per QALY gained of £18,394 
for the target population as a result of better test accuracy and lower detection limit 
relative to Sanger sequencing. The cobas EGFR Mutation test was able to correctly 
identify more patients with EGFR mutations (lower rate of false negatives) and more 
appropriately direct patient treatment than Sanger sequencing. ConClusions: The 
cobas EGFR Mutation Test, by correctly identifying more patients for proper treatment, 
can be considered a cost-effective strategy for identification of EGFR mutations in 
locally advanced or metastatic NSCLC patients from a UK payer perspective.
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objeCtives: To critically appraise published cost-effectiveness analyses (CEAs) of 
human papillomavirus (HPV) testing in cervical screening regarding the appropriate-
ness of comparisons between strategies and the usefulness of the interpretation of 
cost-effectiveness estimates. Methods: The PubMed database was searched for rel-
evant CEAs of cervical screening using HPV testing. The identified CEAs were carefully 
appraised for their quality of analyses, reporting and interpretation of results. Specific 
examples of modelling shortcomings were selected as illustrations of what to avoid 
when estimating the cost-effectiveness of HPV-based screening. Results: The review 
identified 29 relevant CEAs. Regarding basic errors, 11 of the 29 calculated the incremen-
tal cost-effectiveness ratios (ICERs) either partly or completely incorrectly. Ten studies 
failed to fully report costs and effects; either simply reporting ICERs or depicting a 
cost-effectiveness plane. Regarding more fundamental errors, 23 failed to include suf-
ficient screening interval comparators against which to meaningfully estimate ICERs; 
effectively leading to average cost-effectiveness ratios being mistakenly identified as 
ICERs, which biases cost-effectiveness ratio estimates downwards. Finally, none of the 
studies gave specific consideration to the magnitude of the change in costs and effects 
of adding HPV testing to a given strategy, either with a simple graphical interpretation 
or with a formal interpretation using the net benefit framework. ConClusions: Model 
specification is typically the most difficult part of a model-based CEA, whereas simulat-
ing relevant strategies is relatively straightforward once the model is built. Similarly, 
once results have been generated, their correct presentation and interpretation is rela-
tively straightforward. However, this analysis shows that these relatively easy aspects 
of CEA are being performed poorly in the HPV screening literature. Consequently, a few 
simple improvements to basic aspects of CEAs of HPV-based screening could greatly 
enhance the usefulness of such analyses to decision makers.
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objeCtives: ALK-targeted therapy with crizotinib offers significant improvement 
in clinical outcomes for the treatment of EML4–ALK fusion positive NSCLC. We 
estimated the cost-effectiveness of EML4-ALK testing in combination with first-
line crizotinib for ALK positive NSCLC in Ontario. Methods: A cost-effective-
ness analysis was conducted, using a Markov model from the Canadian public 
health (Ontario) perspective and a lifetime horizon in Stage IV NSCLC patients 
with non-squamous histology. Transition probabilities and mortality rates were 
calculated from the Ontario Cancer Registry and Cancer Care Ontario New Drug 
Funding Program (CCO NDFP). Costs were obtained from the Ontario Case Costing 
Initiative, CCO NDFP, University Health Network and the literature. Population-based 
ALK testing included initial IHC testing followed by FISH confirmation for posi-
tive cases. Results: The strategy of genomic testing linked to targeted crizotinib 
treatment gained 0.11 QALYs compared to no testing or crizotinib treatment in the 
advanced non-squamous NSCLC population. The incremental cost was CAD $4,179 
per patient compared to the previous standard of care without ALK testing; the 
incremental cost-effectiveness ratio for the base case was $392,538 per QALY. The 
incremental cost and ICER for crizotinib therapy in known ALK positive advanced 
NSCLC patients was $96,554 and $254,617/QALY. The cost of testing was less rel-
evant to the ICER at a biomarker frequency of 7% and higher. The major drivers 
of cost-effectiveness are drug cost and low biomarker frequency in the popula-
tion. ConClusions: EML4–ALK genomic testing in combination with crizotinib 
treatment for all Stage IV non-squamous NSCLC patients is not cost-effective in the 
setting of high drug costs and a low biomarker frequency in the general population. 
Modifying these key drivers will be important in improving the cost-effectiveness 
and accessibility to novel therapies with major clinical benefit in advanced NSCLC.
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to induction cost and percentage transplants. At a willingness-to-pay threshold 
of 35,000€ per QALY gained, VTD has a 57.1% probability to be cost-effective in 
this setting. ConClusions: VTD induction is a cost-effective strategy for ndMM 
patients eligible for ASCT in Germany compared to TD.
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objeCtives: This analysis compares the cost effectiveness (CE) of an induction 
and maintenance sequence of a cisplatin plus pemetrexed (cis+pem) doublet fol-
lowed by pemetrexed, with that of a bevacizumab (7.5mg or 15mg) plus cispl-
atin plus gemcitabine (bev+cis+gem) triplet followed by bevacizumab (7.5mg or 
15mg) for the treatment of non-squamous non-small cell lung cancer (NSCLC) 
in Sweden. Methods: As no head-to-head trial data are available comparing 
these relevant regimens in the first-line induction and maintenance treatment 
settings, decision modelling and evidence synthesis were used to estimate 
CE. A series of network meta-analyses were performed to obtain hazard ratios 
for overall survival (OS) and progression-free survival (PFS) for each induction 
and maintenance comparator, and odds ratios for response for induction com-
parators. Bevacizumab doses were pooled in the meta-analyses. The CE model 
was structured using an area-under-the-curve approach. Costs and benefits 
were discounted at 3% per annum, consistent with Swedish practice. Results: 
Cis+pem induction followed by pemetrexed maintenance was associated with 
a higher median PFS, OS, total life-years gained and quality-adjusted life-
years (QALYs) than the bevacizumab triplets. Total costs were 416,478Kr for the 
bev(7.5mg)+cis+gem induction triplet plus bevacizumab 7.5mg maintenance 
sequence, 478,862Kr for the cis+pem doublet followed by pemetrexed maintenance 
sequence, and 541,677Kr for the bev(15mg)+cis+gem induction triplet followed 
by bevacizumab 15mg maintenance sequence. Total QALYs were 0.73 and 0.97 
for the bevacizumab triplets and pemetrexed induction and maintenance 
sequence. The incremental cost-effectiveness ratio (ICER) of cis+pem followed by 
pemetrexed compared with bev(7.5mg)+cis+gem followed by bevacizumab 7.5mg 
was 260,831Kr (30,477Euro). The higher bevacizumab dose of 15mg was dominated 
by the cis+pem followed by pemetrexed sequence. The results of the probabilis-
tic analysis support these results. ConClusions: The results of the CE analysis 
suggest that cis+pem doublet induction followed by pemetrexed maintenance is 
a cost-effective treatment sequence compared with the bevacizumab options for 
NSCLC in Sweden.
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objeCtives: To assess the cost-effectiveness of axitinib compared to sorafenib from 
the perspective of a US third-party payer for second-line treatment of patients with 
advanced RCC who failed cytokines. Methods: Phase III AXIS trial reported that 
axitinib increased median progression free survival (PFS) compared to sorafenib 
(12.0 vs. 6.6 months, p< 0.0001), while overall survival (OS) showed no difference 
(29.4 vs. 27.8 months, p= 0.144) in patients failing treatment with cytokines. A cohort 
partition model was constructed to estimate direct medical costs and health out-
comes, discounted at 3.0% per annum. Patients were apportioned into 3 health 
states (progression-free, progressed and dead) based on OS and PFS Kaplan-Meier 
curves from the AXIS trial. Active treatment was applied until progression, fol-
lowed by best supportive care (BSC) thereafter. The wholesale acquisition costs and 
adverse event (AE) costs were obtained from published sources. AE rates and utility 
values were informed by the AXIS trial. US administrative claims data (MarketScan®) 
was analyzed to estimate routine care costs. Probabilistic sensitivity analysis (PSA) 
was conducted. Results: The total per-patient lifetime costs were estimated to be 
$242,750 for axitinib and $168,880 for sorafenib and 84% of the cost difference was 
due to the higher total medication cost of axitinib. The quality-adjusted life-years 
(QALY) gained on axitinib vs. sorafenib was 1.3 vs. 1.2 and the incremental cost-
effectiveness ratio (ICER) was $683,209/QALY. 100% of the PSA iterations showed 
that axitinib was more expensive than sorafenib and the QALY difference between 
axitinib and sorafenib was no greater than 0.7. ConClusions: For post-cytokine 
subgroup, axitinib resulted in an ICER > $650,000/QALY versus sorafenib due to 
high drug costs and lack of OS benefit, indicating that axitinib may not present 
good value for money as 2nd line treatment of advanced RCC when compared to 
sorafenib in the US.
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objeCtives: We explored the cost-effectiveness of using the CE-IVD marked cobas® 
EGFR Mutation Test versus Sanger sequencing for identifying EGFR mutations in locally 
advanced or metastatic NSCLC patients from a UK payer perspective. Methods: A 
decision-tree model was developed to compare testing methodologies and resulting 
